nach oben

Erschienen in:

01.03.2008 | Übersichten

Die Rolle des Androgenrezeptors im hormonrefraktären Prostatakarzinom

Molekulare Grundlagen und experimentelle Therapieansätze

verfasst von: Dr. L. Rinnab, A. Hessenauer, S.V. Schütz, E. Schmid, R. Küfer, F. Finter, R.E. Hautmann, K.D. Spindler, M.V. Cronauer

Erschienen in: Die Urologie | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Entstehung hormonrefraktärer Prostatakarzinomzellen während einer Hormonablationstherapie stellt die Hauptursache für den Tumorprogress und die hohe Mortalitätsrate des fortgeschrittenen Prostatakarzinoms (PCA) dar. Während in vitro der Verlust des Androgenrezeptors (AR) der vorherrschende Mechanismus für die Entwicklung einer Hormoninsensitivität ist, zeigen In-vivo-Untersuchungen, dass die Expression des AR in Zellen hormonrefraktärer PCA weitgehend erhalten bleibt oder sogar gesteigert ist. Die im Hinblick auf die in westlichen Industrienationen kontinuierlich steigende Anzahl an PCA durchgeführten molekularbiologischen bzw. zellbiologischen Untersuchungen führten zur Entdeckung einer Vielzahl neuer Faktoren/Mechanismen, die bei der Entstehung hormonrefraktärer PCA eine Rolle spielen. Diese Erkenntnisse sollten in weiterer Folge zu neuen Therapiekonzepten führen bzw. solche unterstützen.

Hobisch A, Culig Z, Radmayr C et al. (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55: 3068–3072PubMed

Hobisch A, Culig Z, Radmayr C et al. (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28: 129–135PubMedCrossRef

Koivisto P, Kononen J, Palmberg C et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314–319PubMed

Visakorpi T, Hyytinen E, Koivisto P et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401–406PubMedCrossRef

Billas IM, Moras D (2005) Ligand-binding pocket of the ecdysone receptor. Vitam Horm 73: 101–129PubMed

McEwan IJ (2004) Sex, drugs and gene expression: signalling by members of the nuclear receptor superfamily. Essays Biochem 40: 1–10PubMed

Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 95: 1327–1335PubMedCrossRef

Heinlein CA, Chang C (2002) The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16: 2181–2187PubMedCrossRef

Lu S, Jenster G, Epner DE (2000) Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 14: 753–760PubMedCrossRef

10.

Doyu M, Sobue G, Mukai E et al. (1992) Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32: 707–710PubMedCrossRef

11.

Montgomery JS, Price DK, Figg WD (2001) The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 195: 138–146PubMedCrossRef

12.

Hardy DO, Scher HI, Bogenreider T et al. (1996) Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 81: 4400–4405PubMedCrossRef

13.

Giovannucci E, Stampfer MJ, Krithivas K et al. (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94: 3320–3323PubMedCrossRef

14.

Ingles SA, Ross RK, Yu MC et al. (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166–170PubMedCrossRef

15.

Hakimi JM, Schoenberg MP, Rondinelli RH et al. (1997) Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 3: 1599–1608PubMed

16.

Freedman ML, Pearce CL, Penney KL et al. (2005) Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet 76: 82–90PubMedCrossRef

17.

Stanford JL, Just JJ, Gibbs M et al. (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57: 1194–1198PubMed

18.

Correa-Cerro L, Wohr G, Haussler J et al. (1999) (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 7: 357–362PubMedCrossRef

19.

Newmark JR, Hardy DO, Tonb DC et al. (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89: 6319–6323PubMedCrossRef

20.

Lin DL, Whitney MC, Yao Z, Keller ET (2001) Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 7: 1773–1781PubMed

21.

Culig Z, Hobisch A, Cronauer MV et al. (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541–1550PubMedCrossRef

22.

Brooke GN, Parker MG, Bevan CL (2007) Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene (Epub, doi: 10.1038/sj.onc.1210955)

23.

Cronauer MV, Schulz WA, Burchardt T et al. (2003) The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol 23: 1095–1102PubMed

24.

Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45PubMedCrossRef

25.

Haelens A, Tanner T, Denayer S et al. (2007) The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 67: 4514–4523PubMedCrossRef

26.

Gregory CW, He B, Johnson RT et al. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315–4319PubMed

27.

Chen CD, Welsbie DS, Tran C et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33–39PubMedCrossRef

28.

Titus MA, Schell MJ, Lih FB et al. (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653–4657PubMedCrossRef

29.

Nakayama T, Watanabe M, Suzuki H et al. (2000) Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 80: 1789–1796PubMedCrossRef

30.

Cronauer MV, Hittmair A, Eder IE et al. (1997) Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31: 223–233PubMedCrossRef

31.

Culig Z, Hobisch A, Cronauer MV et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474–5478PubMed

32.

Godoy-Tundidor S, Cavarretta IT, Fuchs D et al. (2005) Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate 64: 209–216PubMedCrossRef

33.

Signoretti S, Montironi R, Manola J et al. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918–1925PubMedCrossRef

34.

Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280–285PubMedCrossRef

35.

McKenna NJ, O’Malley BW (2002) Minireview: nuclear receptor coactivators – an update. Endocrinology 143: 2461–2465PubMedCrossRef

36.

Heemers HV, Sebo TJ, Debes JD et al. (2007) Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67: 3422–3430PubMedCrossRef

37.

Kang HY, Yeh S, Fujimoto N, Chang C (1999) Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274: 8570–8576PubMedCrossRef

38.

Kobayashi M, Honma T, Matsuda Y et al. (2000) Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer 82: 1689–1693PubMedCrossRef

39.

Roose J, Clevers H (1999) TCF transcription factors: molecular switches in carcinogenesis. Biochem Biophys Acta 1424: 23–37

40.

Oving IM, Clevers HC (2002) Molecular causes of colon cancer. Eur J Clin Invest 32: 448–457PubMedCrossRef

41.

Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1: 55–67PubMedCrossRef

42.

Wetering M van de, Sancho E, Verweij C et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241–250PubMedCrossRef

43.

Gounari F, Signoretti S, Bronson R et al. (2002) Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21: 4099–4107PubMedCrossRef

44.

Bierie B, Nozawa M, Renou JP et al. (2003) Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22: 3875–3887PubMedCrossRef

45.

Chesire DR, Isaacs WB (2003) Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer 10: 537–560PubMedCrossRef

46.

Yang F, Li X, Sharma M et al. (2002) Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277: 11336–11344PubMedCrossRef

47.

Truica CI, Byers S, Gelmann EP (2000) Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60: 4709–4713PubMed

48.

Cronauer MV, Schulz WA, Ackermann R, Burchardt M (2005) Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 26: 1033–1040PubMed

49.

Cronauer MV, Ince Y, Engers R et al. (2007) Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 26: 1875–1884PubMedCrossRef

50.

Rogatsky I, Waase CL, Garabedian MJ (1998) Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3). Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. J Biol Chem 273: 14315–14321PubMedCrossRef

51.

Salas TR, Kim J, Vakar-Lopez F et al. (2004) Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279: 19191–19200PubMedCrossRef

52.

Medunjanin S, Hermani A, De Servi B et al. (2005) Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J Biol Chem 280: 33006–33014PubMedCrossRef

53.

Chen S, Xu Y, Yuan X et al. (2006) Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103: 15969–15974PubMedCrossRef

54.

Gotz C, Kartarius S, Schetting S, Montenarh M (2005) Immunologically defined subclasses of the protein kinase CK2 beta-subunit in prostate carcinoma cell lines. Mol Cell Biochem 274: 181–187PubMedCrossRef

55.

Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369: 1–15PubMedCrossRef

56.

Hessenauer A, Montenarh M, Gotz C (2003) Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 22: 1263–1270PubMed

57.

Slaton JW, Unger GM, Sloper DT et al. (2004) Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2: 712–721PubMed

58.

Laramas M, Pasquier D, Filhol O et al. (2007) Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 43: 928–934PubMedCrossRef

59.

Cronauer MV, Schulz WA, Burchardt T et al. (2004) Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23: 3541–3549PubMedCrossRef

60.

Peterziel H, Mink S, Schonert A et al. (1999) Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18: 6322–6329PubMedCrossRef

61.

Unni E, Sun S, Nan B et al. (2004) Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64: 7156–7168PubMedCrossRef

62.

Makridakis N, Ross RK, Pike MC et al. (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 57: 1020–1022PubMed

63.

Nikitin AY, Matoso A, Roy-Burman P (2007) Prostate stem cells and cancer. Histol Histopathol 22: 1043–1049PubMed

64.

Richardson GD, Robson CN, Lang SH et al. (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117: 3539–3545PubMedCrossRef

65.

Collins AT, Berry PA, Hyde C et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946–10951PubMedCrossRef

66.

Cantin L, Faucher F, Couture JF et al. (2007) Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally-designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem 282(42): 30910–30919PubMedCrossRef

67.

Eder IE, Hoffmann J, Rogatsch H et al. (2002) Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9: 117–125PubMedCrossRef

68.

Haag P, Bektic J, Bartsch G et al. (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96: 251–258PubMedCrossRef

69.

Haag P, Frauscher F, Gradl J et al. (2006) Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J Steroid Biochem Mol Biol 102: 103–113PubMedCrossRef

70.

Neckers L (2002) Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 8: 962–966PubMed

71.

Kamal A, Thao L, Sensintaffar J et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407–410PubMedCrossRef

72.

Solit DB, Zheng FF, Drobnjak M et al. (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986–993PubMed

73.

Heath EI, Gaskins M, Pitot HC et al. (2005) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4: 138–141PubMed

74.

Agus DB, Scher HI, Higgins B et al. (1999) Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 59: 4761–4764PubMed

75.

Hammarsten P, Rudolfsson SH, Henriksson R et al. (2007) Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats. Prostate 67: 573–581PubMedCrossRef

76.

Sepp-Lorenzino L, Tjaden G, Moasser MM et al. (2001) Farnesyl: protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate Cancer Prostatic Dis 4: 33–43PubMedCrossRef

77.

Formento P, Hannoun-Levi JM, Gerard F et al. (2005) Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur J Cancer 41: 1467–1473PubMedCrossRef

78.

Curigliano G, De Braud F, Teresa Sandri M et al. (2007) Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. Anticancer Drugs 18: 949–954PubMed

79.

Lara PN Jr, Chee KG, Longmate J et al. (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100: 2125–2131PubMedCrossRef

80.

Ziada A, Barqawi A, Glode LM et al. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332–337PubMedCrossRef

81.

Diaz LA MW, Carducci M, Pili R et al. (2007) Infliximab in patients with hormone refractory prostate cancer and bone metastases with pain. Abstractband ASCO 2007, p 268

82.

Grisouard J, Medunjanin S, Hermani A et al. (2007) Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol, Epub, doi:10.1210/me.2007-0129

83.

Mazor M, Kawano Y, Zhu H et al. (2004) Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 23: 7882–7892PubMedCrossRef

84.

Wang L, Lin HK, Hu YC et al. (2004) Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 279: 32444–32452PubMedCrossRef

85.

Liao X, Thrasher JB, Holzbeierlein J et al. (2004) Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145: 2941–2949PubMedCrossRef

86.

Kroncke KD, Carlberg C (2000) Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide. FASEB J 14: 166–173PubMed

87.

Garban HJ, Marquez-Garban DC, Pietras RJ, Ignarro LJ (2005) Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci USA 102: 2632–2636PubMedCrossRef

88.

Cronauer MV, Stadlmann S, Klocker H et al. (1999) Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. Am J Pathol 155: 1977–1984PubMed

89.

Mizokami A, Saiga H, Matsui T et al. (1992) Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol Jpn 39: 235–243PubMed

90.

Henttu P, Vihko P (1993) Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 53: 1051–1058PubMed

91.

Adam RM, Kim J, Lin J et al. (2002) Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 143: 4599–4608PubMedCrossRef

92.

Culig Z, Hobisch A, Herold M et al. (1998) Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Br J Cancer 78: 1004–1011PubMed

93.

Hobisch A, Eder IE, Putz T et al. (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640–4645PubMed

94.

Godoy-Tundidor S, Hobisch A, Pfeil K et al. (2002) Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 8: 2356–2361PubMed

Titel: Die Rolle des Androgenrezeptors im hormonrefraktären Prostatakarzinom
Molekulare Grundlagen und experimentelle Therapieansätze
verfasst von: Dr. L. Rinnab
A. Hessenauer
S.V. Schütz
E. Schmid
R. Küfer
F. Finter
R.E. Hautmann
K.D. Spindler
M.V. Cronauer
Publikationsdatum: 01.03.2008
Verlag: Springer-Verlag
Erschienen in: Die Urologie / Ausgabe 3/2008
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-008-1637-1

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Die Rolle des Androgenrezeptors im hormonrefraktären Prostatakarzinom

Molekulare Grundlagen und experimentelle Therapieansätze

Zusammenfassung

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Update Urologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Die extendierte Sentinel-Lymphadenektomie im Rahmen der radikalen Prostatektomie?

Die Rolle des Gleitmittels bei der transurethralen Elektroresektion

Brachytherapie des Prostatakarzinoms

URO-Telegramm

Einschmelzende Entzündungen perineal und skrotal

Berufspolitik BDU

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Update Urologie